Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
NCT ID: NCT07290543
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
578 participants
INTERVENTIONAL
2025-08-26
2032-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Co-design Objective (Aim 1): Finalize the CONNECT digital tool design through qualitative co-design evaluations with stakeholders to prepare the intervention for efficacy testing.
II. Efficacy Objective (Aim 2): Evaluate the efficacy of the CONNECT digital tool in reducing cancer-related distress among rural cancer survivors and caregivers, as measured by the validated 23-item Cancer and Treatment Distress Scale (CTXD), in a randomized controlled trial.
III. Implementation Objective (Aim 3): Assess the feasibility and potential for scale-up of the CONNECT intervention in rural communities and healthcare settings through qualitative interviews.
SECONDARY OBJECTIVES:
I. Assess self-reported healthcare resource utilization over the 12-month study period. (Aim 2, Efficacy Testing)
II. Assess self-reported shared device use for accessing health-related information and services. (Aim 2, Efficacy Testing)
III. Assess self-reported telehealth utilization, including portal use, completed visits, and visit modality. (Aim 2, Efficacy Testing)
IV. Evaluate cancer survivors' unmet needs using a validated 35-item unmet needs survey. (Aim 2, Efficacy Testing)
V. Evaluate caregiver strain using the validated 13-item Caregiver Strain Index. (Aim 2, Efficacy Testing)
OUTLINE: Advisory board members are assigned to arm I, patients and their caregivers are randomized to arm II or III.
ARM I: Co-design / Advisory Board Arm (Non-randomized) Advisory board members participate in qualitative co-design activities to refine the CONNECT digital tool prior to efficacy testing. Activities include small-group workshops, interviews, field-testing, and surveys focused on usability, content relevance, and acceptability of the platform.
ARM II: Intervention (CONNECT) Arm: Participants receive access to the CONNECT digital platform, which includes educational materials on cancer-related distress management, guidance on telehealth use, and personalized recommendations for supportive resources. They complete a guided onboarding tutorial with a Study Team Member, receive up to four structured review sessions (20 minutes each) by phone or video, and get automated text message reminders every two weeks for four months to encourage engagement.
Control Arm: Participants receive usual care plus a mailed educational brochure about managing cancer-related distress. They do not receive access to the CONNECT platform or coaching sessions.
ARM III: Patients are mailed an educational brochure about distress management on study. AIM 3: Scale-up / Implementation Assessment A subsample of participants from Arms II and III will participate in exit interviews to assess potential implementation outcomes, sustainability, and barriers/facilitators for scaling CONNECT in rural communities and healthcare settings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (Advisory board)
Advisory board members complete small group workshops, interviews and surveys on study.
Interview
Complete interview
Interview
Complete small group workshop
Survey Administration
Ancillary study
Arm II (CONNECT platform)
Patients and their caregivers receive access to the CONNECT platform, which includes educational materials on distress management, guides to telehealth and personalized recommendations for resources. Patients and their caregivers complete a guided tutorial of the platform with a research assistant at the start of the intervention period, receive biweekly phone calls with the research assistant, for 20 minutes starting on 14 days to 2 months to review the four cancer-related management functions and receive a text message reminders to encourage use, every 2 weeks for 4 months.
Educational Intervention
Receive educational materials on distress management and guides to telehealth
Internet-Based Intervention
Receive access to CONNECT platform
Interview
Complete interview
Patient Navigation
Receive personalized recommendations for resources
Survey Administration
Ancillary study
Telephone-Based Intervention
Complete calls with research assistant
Text Message-Based Navigation Intervention
Receive text message reminders
Arm III (Educational brochure)
Patients are mailed an educational brochure about distress management on study.
Educational Intervention
Receive written educational brochure about distress management
Interview
Complete interview
Survey Administration
Ancillary study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Educational Intervention
Receive educational materials on distress management and guides to telehealth
Educational Intervention
Receive written educational brochure about distress management
Internet-Based Intervention
Receive access to CONNECT platform
Interview
Complete interview
Interview
Complete small group workshop
Patient Navigation
Receive personalized recommendations for resources
Survey Administration
Ancillary study
Telephone-Based Intervention
Complete calls with research assistant
Text Message-Based Navigation Intervention
Receive text message reminders
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AIM 1: In the following or related field:
* Healthcare professionals (physicians, nurses, pharmacists, etc.)
* Patient advocates and representatives
* Researchers in healthcare or technology fields
* Healthcare administrators and managers
* AIM 1: Must be over 18 years old
* AIM 1: English-speaking
* AIM 1: Willing and able to provide informed consent
* AIM 2 (RURAL OLDER CANCER SURVIVORS): A rural resident based on the Health Resources \& Services Administration (HRSA) rural analyzer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report of diagnosis with any cancer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report posttreatment (i.e., completion of curative intent therapy including surgery, chemotherapy, molecularly targeted, and endocrine therapy)
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Have access to a computer, a smartphone, or a tablet computer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Aged \> 65 years old
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Assessed as having Cancer and Treatment Distress scale (CTXD) scores \> 0.85 at screening
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Have a caregiver willing to participate
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Non-institutionalized
* AIM 2 (RURAL OLDER CANCER SURVIVORS): English proficient
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Willing and able to provide informed consent
* AIM 2 (CAREGIVER): An identified informal caregiver of an eligible ROCS (caregivers include, but are not limited to, a child, partner, or friend; caregivers can reside in a rural or urban area and may or may not live with the ROCS
* AIM 2 (CAREGIVER): Have internet access
* AIM 2 (CAREGIVER): ≥ 18 years old
* AIM 2 (CAREGIVER): Non-institutionalized
* AIM 2 (CAREGIVER): English proficient
* AIM 2 (CAREGIVER): Willing and able to provide informed consent
* AIM 3 (FINAL WORKSHOP): Includes providers, medical and practice managers, patient care coordinators, and medical health technologists
Exclusion Criteria
* AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Are inpatients
* AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Cognitive impairment precludes the ability to provide written consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institute of Nursing Research (NINR)
NIH
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marquita W Lewis, PhD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwestern University
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marquita W. Lewis
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-09384
Identifier Type: REGISTRY
Identifier Source: secondary_id
STU00222660
Identifier Type: -
Identifier Source: secondary_id
NU 24CC20
Identifier Type: OTHER
Identifier Source: secondary_id
NU 24CC20
Identifier Type: -
Identifier Source: org_study_id